Abstract:Thalassemia is one of the most common monogenic diseases in southern China1. Carriers of thalassemia are usually asymptomatic. However, they have a 25% chance of having symptomatic children if their spouses are also carriers of the same type of thalassemia. Fetuses with homozygous α0-thalassemia usually die in utero during the third trimester or in the early neonatal period, although there are some case reports of long-term survival after intrauterine transfusion therapy2. On the other hand, children with β-thalassemia major usually require life-long blood transfusion for normal growth and development. A prospective prenatal diagnosis program has been carried out to prevent thalassemia at our hospital since 19933. During this period, we encountered two cases in which the pregnant women were referred to prenatal diagnosis for β-thalassemia; however, the fetuses were found to be suffering from homozygous α-thalassemia. Family 1 was referred to our center for prenatal diagnosis in the mother's first trimester of gestation. This was her second pregnancy. Their first son had suffered from severe homozygous β-thalassemia and had been regularly transfused. The child had died at 2 years of age. Both parents had classical β-thalassemia trait based on hematological testing (Table 1). Molecular analysis revealed that the father had a heterozygous β-thalassemia IVS-II-654 (C → T) mutation and the mother a heterozygous β-thalassemia codons 41/42 (–TCTT) mutation. Chorionic villus sampling was then performed at 12 weeks of gestation, and genotyping of the sampled villi showed that the fetus had inherited only the maternal codons 41/42 (–TCTT) mutation. This finding suggested that the phenotype of the fetus was a carrier. The mother continued her pregnancy. However, an additional ultrasound examination at 15 weeks because of vaginal spotting identified fetal cardiomegaly (≥ 0.5 at 12–17 weeks) and placentomegaly (> 18 mm at 12–15 weeks)4. The cardiothoracic ratio was 0.53 and placental depth was 3.2 cm. These signs led us to exclude Hb Bart's hydrops fetalis in an area with high prevalence of thalassemia. The frozen DNA samples of the family were retrieved, and α-globin genotyping revealed that both parents had heterozygous α0-thalassemia (--SEA(SoutheastAsian)) and the fetus had homozygous α0-thalassemia (--SEA/--SEA). The pregnancy was terminated at 16 weeks of gestation at the parents' request. Family 2 was referred to our center for prenatal diagnosis at 18 weeks of gestation. This was the mother's first pregnancy. Both parents were found to be positive for β-thalassemia by hematological testing (Table 1). Molecular analysis revealed that both parents had a heterozygous β-thalassemia IVS-II-654 (C → T) mutation. An anatomical scan before invasive testing identified fetal cardiomegaly (≥ 0.52 at 18–20 weeks), with a cardiothoracic ratio of 0.56 and a placental depth of 3.5 cm. The decision was made to sample the fetal blood. Hb Bart's hydrops fetalis syndrome was confirmed, with the following hematological findings: Hb Bart's 76.6%, Hb (A + Portland) 23.4%, HbF 0% and HbA2 0%. Genotyping of α-globin showed that both parents had co-existent α0-thalassemia (--SEA) and the fetus had homozygous α0 thalassemia (--SEA/--SEA). The pregnancy was terminated at 19 weeks of gestation. The carrier rates of α0-thalassemia (--SEA) and β-thalassemia are 4.1% and 2.5%, respectively, in southern China1. This means that the chance of finding an individual with co-inheritance of α0- and β-thalassemia in the population is theoretically 1/1000. In other words, one in every 25 β-thalassemia carriers co-inherits α0-thalassemia. It is well known that routine screening testing, such as mean cell volume (MCV) and HbA2 level, cannot distinguish double heterozygotes of α- and β-thalassemia from the pure heterozygous β-thalassemia state5-7. DNA diagnosis is necessary for differentiation. Diagnosis of this double heterozygotic state is important for genetic counseling, since, unlike the typical β-thalassemia carriers, these individuals will be at risk of having offspring with homozygous α0-thalassemia if their partners are also α0-thalassemia heterozygotes. Hence, in our prenatal thalassemia screening program, we determine by molecular analysis the α0-thalassemia status in β-thalassemia partners in couples presumed to be discordant for α- and β-thalassemia on hematological findings8. However, when both members of a couple are found on screening to be β-thalassemia carriers, it may not be cost-effective to perform α-globin genotyping on both partners. In this situation, the chance of delivering a homozygous α0-thalassemia offspring is remote (theoretically 1/2500). However, one should be aware of the risk of their pregnancies being affected by homozygous α0-thalassaemia. Since invasive prenatal testing is always necessary for these β-thalassemia at-risk pregnancies, simultaneously determining the α-globin genotype of the fetus is a method of choice. Another option is to perform serial ultrasound examinations to exclude an affected pregnancy from 12 weeks of gestation4. C. Liao*, X.-M. Xie*, D.-Z. Li*, * Prenatal Diagnostic Center, Guangzhou Maternal and Neonatal Hospital, Guangzhou Medical College, Guangzhou, Guangdong 510180, People's Republic of China

Neonatal Screening for Α‐thalassemia by Cord Hemoglobin Barts: How Effective is It?

Prevention of Hb Bart’s (γ4) Disease Associated with the – –Thaiα0-Thalassemia Deletion in Mainland China

Application value of fetal umbilical cord blood hemoglobin analysis in prenatal diagnosis of thalassemia

Screening of α-thalassemia in umbilical cord blood of 532 neonates in Guiyang city

Prenatal diagnostic errors in hemoglobin Bart's hydrops fetalis caused by rare genetic interactions of α-thalassemia

Relationship between neonatal screening results by HPLC and the number of α-thalassaemia gene mutations; consequences for the cut-off value

Analysis of Hemoglobin Electrophoresis of Cord Blood Samples from Newborn Infants with Different Gestational Weeks

Noninvasive Prenatal Detection of Hemoglobin Bart Hydrops Fetalis Via Maternal Plasma Dispensed with Parental Haplotyping Using the Semiconductor Sequencing Platform.

Application of an optimized interpretation model in capillary hemoglobin electrophoresis for newborn thalassemia screening

Evaluation of cardiac findings using speckle tracking in fetuses with hemoglobin Bart's disease

Two Cases of Homozygous Alpha0-Thalassemia Diagnosed Prenatally in Pregnancies at Risk for Beta-Thalassemia in China.

Comprehensive analysis of thalassemia alleles (CATSA) based on third-generation sequencing is a comprehensive and accurate approach for neonatal thalassemia screening

A Path toward Universal Screening

[Application of Next Generation Sequencing to Screen the Neonatal Thalassemia Genes]

Application of capillary electrophoresis for screening of the β-thalassemia in neonates

Newborn Screening for β-Thalassemia Identifies a Complex Genotype Involving a Novel β-Globin Gene Mutation (HBB:c.336dup)

Microcolumn and Coelution Hydration of Oil Seal Blood Spot for Efficient Screening of Newborn Α-Thalassemia Via Chip Isoelectric Focusing

Update in Laboratory Diagnosis of Thalassemia

Study on Prenatal Screening and Genotype Analysis of Α-Thalassemia

Hydrops Fetalis Associated with Compound Heterozygosity for Hb Zurich-Albisrieden (HBA2: C.178G > C) and the Southeast Asian (- - SEA /) Deletion.

Invasive Molecular Prenatal Diagnosis of Alpha and Beta Thalassemia among Hakka Pregnant Women